Yackov Berkun
YOU?
Author Swipe
View article: A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity
A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity Open
Autosomal recessive deficiency of the IFNAR1 or IFNAR2 chain of the human type I IFN receptor abolishes cellular responses to IFN-α, -β, and -ω, underlies severe viral diseases, and is globally very rare, except for IFNAR1 and IFNAR2 defic…
View article: Successful Haematopoietic Stem Cell Transplantation for LRBA Deficiency with Fludarabine, Treosulfan, and Thiotepa-Based Conditioning
Successful Haematopoietic Stem Cell Transplantation for LRBA Deficiency with Fludarabine, Treosulfan, and Thiotepa-Based Conditioning Open
LRBA deficiency is an inborn error of immunity defined by autoimmunity, lymphoproliferation, recurrent infections, cytopenia, and inflammatory bowel disease. Despite recent advances in managing this disease with targeted biologic therapy, …
View article: Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS
Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS Open
We observed disease flares and rebound inflammation with baricitinib dose reductions and proposed flare criteria that can assist in monitoring disease activity and in designing clinical studies in CANDLE/PRAAS.
View article: 2023 ACR/EULAR antiphospholipid syndrome classification criteria
2023 ACR/EULAR antiphospholipid syndrome classification criteria Open
View article: Evaluation and Management of Deficiency of Adenosine Deaminase 2
Evaluation and Management of Deficiency of Adenosine Deaminase 2 Open
Importance Deficiency of adenosine deaminase 2 (DADA2) is a recessively inherited disease characterized by systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency affecting both children and adults. DADA2 is a…
View article: Pediatric respiratory admissions and related viral infections during the COVID‐19 pandemic
Pediatric respiratory admissions and related viral infections during the COVID‐19 pandemic Open
Introduction The COVID‐19 pandemic has affected the incidence of respiratory viral infections. Our aim was to assess changes in pediatric admissions due to respiratory diseases and associated respiratory viral infections. Methods An observ…
View article: Supplementary Figure 3 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 3 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 42KB, MRG1 synergizes with adoptively transferred human TIL in xenograft model.
View article: Supplementary References from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary References from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 40KB.
View article: Supplementary Figure 2 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 2 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 32KB, Validation of the immune-protective effect of CEACAM1 in CEACAM1-silenced melanoma cells.
View article: Supplementary Figure 1 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 1 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 277KB, MRG1 specifically recognizes the N-domain of the CEACAM1 protein and has a high binding affinity.
View article: Supplementary Figure Legend from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure Legend from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 43KB.
View article: Supplementary Figure 5 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 5 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 57KB, The effect of MRG1 was not mediated by ADCC.
View article: Supplementary Figure 3 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 3 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 42KB, MRG1 synergizes with adoptively transferred human TIL in xenograft model.
View article: Supplementary Figure Legend from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure Legend from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 43KB.
View article: Supplementary Figure 1 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 1 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 277KB, MRG1 specifically recognizes the N-domain of the CEACAM1 protein and has a high binding affinity.
View article: Data from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Data from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
CEACAM1 (biliary glycoprotein-1, CD66a) was reported as a strong clinical predictor of poor prognosis in melanoma. We have previously identified CEACAM1 as a tumor escape mechanism from cytotoxic lymphocytes. Here, we present substantial e…
View article: Supplementary Figure 5 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 5 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 57KB, The effect of MRG1 was not mediated by ADCC.
View article: Supplementary Figure 6 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 6 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 39KB, Quantification of CEACAM1 molecules in normal cell strains and melanoma cell lines.
View article: Supplementary Figure 4 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 4 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 54KB, Stability of CEACAM1 expression on injected T cells and its persistence in in vivo model.
View article: Supplementary Methods from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Methods from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 55KB.
View article: Supplementary Figure 4 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 4 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 54KB, Stability of CEACAM1 expression on injected T cells and its persistence in in vivo model.
View article: Data from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Data from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
CEACAM1 (biliary glycoprotein-1, CD66a) was reported as a strong clinical predictor of poor prognosis in melanoma. We have previously identified CEACAM1 as a tumor escape mechanism from cytotoxic lymphocytes. Here, we present substantial e…
View article: Supplementary Figure 6 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 6 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 39KB, Quantification of CEACAM1 molecules in normal cell strains and melanoma cell lines.
View article: Supplementary Methods from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Methods from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 55KB.
View article: Supplementary References from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary References from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 40KB.
View article: Supplementary Figure 2 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Supplementary Figure 2 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions Open
PDF file, 32KB, Validation of the immune-protective effect of CEACAM1 in CEACAM1-silenced melanoma cells.
View article: Risk factors for haemodynamic compromise in multisystem inflammatory syndrome in children: a multicentre retrospective study
Risk factors for haemodynamic compromise in multisystem inflammatory syndrome in children: a multicentre retrospective study Open
Objectives To identify predictors of a severe clinical course of multisystem inflammatory syndrome in children (MIS-C), as defined by the need for inotropic support. Methods This retrospective study included patients diagnosed with MIS-C (…
View article: Multisystem inflammatory syndrome in children associated with COVID‐19 presenting as cervical inflammation
Multisystem inflammatory syndrome in children associated with COVID‐19 presenting as cervical inflammation Open
Aim The major clinical manifestations multisystem inflammatory syndrome in children (MIS‐C) are fever, gastrointestinal and cardiac. The aim of this study was to describe MIS‐C in a series of patients who presented primarily with cervical …
View article: Sechs Fälle von Pityriasis rosea nach SARS‐CoV‐2‐Impfung mit BNT162b2
Sechs Fälle von Pityriasis rosea nach SARS‐CoV‐2‐Impfung mit BNT162b2 Open
View article: Case Series of Myocarditis Following mRNA COVID Vaccine Compared to Pediatric Multisystem Inflammatory Syndrome: Multicenter Retrospective Study
Case Series of Myocarditis Following mRNA COVID Vaccine Compared to Pediatric Multisystem Inflammatory Syndrome: Multicenter Retrospective Study Open
Introduction: Since the development of COVID-19 vaccines, more than 4.8 billion people have been immunized worldwide. Soon after vaccinations were initiated, reports on cases of myocarditis following the second vaccine dose emerged. This s…